FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016025876> ?p ?o ?g. }

• W2016025876 endingPage "556" @default.
• W2016025876 startingPage "550" @default.
• W2016025876 abstract "Abstract Context: 11β-Hydroxysteroid dehydrogenase type 1 (11βHSD1) is a promising target for the treatment of type 2 diabetes mellitus. 11βHSD1 catalyzes the intracrine conversion of inactive cortisone to the active glucocorticoid cortisol. Objective: Demonstrating inhibition of 11βHSD1 is challenging because there is no accessible way to directly assess the enzyme activity in vivo. Thus, it was proposed to assess the enzyme activity, in an indirect fashion, using two biomarker methods: the prednisolone generation study (conversion of oral prednisone to prednisolone in plasma) and the ratio of cortisol and cortisone metabolites in urine. Design: This was a phase 1, double-blind, placebo-controlled, randomized, multiple-dose study. Setting: The study was conducted in a clinical research unit. Participants: Sixty healthy adult volunteers participated in the study. Intervention: Oral doses of PF-00915275 (0.3–15 mg) and prednisone (10 mg) were administered during the study. Main Outcome Measures: Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-00915275, a selective 11βHSD1 inhibitor, were measured. Results: Overall, multiple oral doses of PF-00915275 were safe and well tolerated. After oral administration, PF-00915275 was rapidly absorbed, slowly eliminated, and generally displayed dose-proportional increases in exposure. At the 15-mg dose, mean exposure to prednisolone was reduced by 37%, and there was a dose-dependent fall in the 5α-tetrahydrocortisol + 5β-tetrahydrocortisol to tetrahydrocortisone ratio with maximum inhibition of 26% after 14 d. The urinary free cortisol to urinary free cortisone ratio, an indicator of 11βHSD2 inhibition, did not change. Conclusion: PF-00915275 was safe at all doses tested. The results of the prednisolone generation test and the urinary metabolite ratios confirm that PF-00915275 is a selective 11βHSD1 inhibitor." @default.
• W2016025876 created "2016-06-24" @default.
• W2016025876 creator A5014294005 @default.
• W2016025876 creator A5030649873 @default.
• W2016025876 creator A5037077908 @default.
• W2016025876 creator A5050877182 @default.
• W2016025876 creator A5072950568 @default.
• W2016025876 creator A5084220816 @default.
• W2016025876 date "2008-02-01" @default.
• W2016025876 modified "2023-10-18" @default.
• W2016025876 title "Modulation of 11β-Hydroxysteroid Dehydrogenase (11βHSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11βHSD1 Inhibitor" @default.
• W2016025876 cites W2016295022 @default.
• W2016025876 cites W2020267609 @default.
• W2016025876 cites W2046645679 @default.
• W2016025876 cites W2072352119 @default.
• W2016025876 cites W2092020543 @default.
• W2016025876 cites W2100159933 @default.
• W2016025876 cites W2106964822 @default.
• W2016025876 cites W2117268230 @default.
• W2016025876 cites W2130203112 @default.
• W2016025876 cites W2150654293 @default.
• W2016025876 cites W2154972651 @default.
• W2016025876 cites W2158530640 @default.
• W2016025876 cites W2164058090 @default.
• W2016025876 cites W2164828732 @default.
• W2016025876 cites W2165698647 @default.
• W2016025876 doi "https://doi.org/10.1210/jc.2007-1912" @default.
• W2016025876 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17986636" @default.
• W2016025876 hasPublicationYear "2008" @default.
• W2016025876 type Work @default.
• W2016025876 sameAs 2016025876 @default.
• W2016025876 citedByCount "85" @default.
• W2016025876 countsByYear W20160258762012 @default.
• W2016025876 countsByYear W20160258762013 @default.
• W2016025876 countsByYear W20160258762014 @default.
• W2016025876 countsByYear W20160258762015 @default.
• W2016025876 countsByYear W20160258762016 @default.
• W2016025876 countsByYear W20160258762017 @default.
• W2016025876 countsByYear W20160258762018 @default.
• W2016025876 countsByYear W20160258762019 @default.
• W2016025876 countsByYear W20160258762020 @default.
• W2016025876 countsByYear W20160258762021 @default.
• W2016025876 countsByYear W20160258762022 @default.
• W2016025876 crossrefType "journal-article" @default.
• W2016025876 hasAuthorship W2016025876A5014294005 @default.
• W2016025876 hasAuthorship W2016025876A5030649873 @default.
• W2016025876 hasAuthorship W2016025876A5037077908 @default.
• W2016025876 hasAuthorship W2016025876A5050877182 @default.
• W2016025876 hasAuthorship W2016025876A5072950568 @default.
• W2016025876 hasAuthorship W2016025876A5084220816 @default.
• W2016025876 hasBestOaLocation W20160258761 @default.
• W2016025876 hasConcept C111113717 @default.
• W2016025876 hasConcept C112705442 @default.
• W2016025876 hasConcept C126322002 @default.
• W2016025876 hasConcept C134018914 @default.
• W2016025876 hasConcept C142724271 @default.
• W2016025876 hasConcept C151730666 @default.
• W2016025876 hasConcept C166075782 @default.
• W2016025876 hasConcept C181199279 @default.
• W2016025876 hasConcept C185592680 @default.
• W2016025876 hasConcept C197934379 @default.
• W2016025876 hasConcept C204787440 @default.
• W2016025876 hasConcept C27081682 @default.
• W2016025876 hasConcept C2776317432 @default.
• W2016025876 hasConcept C2776715498 @default.
• W2016025876 hasConcept C2778375690 @default.
• W2016025876 hasConcept C2778720950 @default.
• W2016025876 hasConcept C2779343474 @default.
• W2016025876 hasConcept C2780484280 @default.
• W2016025876 hasConcept C2780841215 @default.
• W2016025876 hasConcept C55493867 @default.
• W2016025876 hasConcept C71924100 @default.
• W2016025876 hasConcept C86803240 @default.
• W2016025876 hasConcept C98274493 @default.
• W2016025876 hasConceptScore W2016025876C111113717 @default.
• W2016025876 hasConceptScore W2016025876C112705442 @default.
• W2016025876 hasConceptScore W2016025876C126322002 @default.
• W2016025876 hasConceptScore W2016025876C134018914 @default.
• W2016025876 hasConceptScore W2016025876C142724271 @default.
• W2016025876 hasConceptScore W2016025876C151730666 @default.
• W2016025876 hasConceptScore W2016025876C166075782 @default.
• W2016025876 hasConceptScore W2016025876C181199279 @default.
• W2016025876 hasConceptScore W2016025876C185592680 @default.
• W2016025876 hasConceptScore W2016025876C197934379 @default.
• W2016025876 hasConceptScore W2016025876C204787440 @default.
• W2016025876 hasConceptScore W2016025876C27081682 @default.
• W2016025876 hasConceptScore W2016025876C2776317432 @default.
• W2016025876 hasConceptScore W2016025876C2776715498 @default.
• W2016025876 hasConceptScore W2016025876C2778375690 @default.
• W2016025876 hasConceptScore W2016025876C2778720950 @default.
• W2016025876 hasConceptScore W2016025876C2779343474 @default.
• W2016025876 hasConceptScore W2016025876C2780484280 @default.
• W2016025876 hasConceptScore W2016025876C2780841215 @default.
• W2016025876 hasConceptScore W2016025876C55493867 @default.
• W2016025876 hasConceptScore W2016025876C71924100 @default.
• W2016025876 hasConceptScore W2016025876C86803240 @default.
• W2016025876 hasConceptScore W2016025876C98274493 @default.
• W2016025876 hasIssue "2" @default.

• next